FMP
MiNK Therapeutics, Inc.
INKT
NASDAQ
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
0.9 USD
0.0288 (3.2%)
About
ceo
Dr. Jennifer S. Buell Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://minktherapeutics.com
exchange
NASDAQ
Description
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
CIK
0001840229
ISIN
US6036931029
CUSIP
603693102
Address
149 Fifth Avenue
Phone
212 994 8250
Country
US
Employee
31
IPO Date
Oct 15, 2021
Summary
CIK
0001840229
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
603693102
ISIN
US6036931029
Country
US
Price
0.9
Beta
0.12
Volume Avg.
97.72k
Market Cap
31.23M
Shares
-
52-Week
0.75-3.34
DCF
0.1
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.38
P/B
-
Website
https://minktherapeutics.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest INKT News
It looks like there's no news available.
